OXFORD(TM) MENISCAL UNICOMPARTMENTAL KNEE SYSTEM
Biomet Manufacturing Corp · Decision date Apr 21, 2004
What did the FDA approve?
FDA approved the Oxford Meniscal Unicompartmental Knee System (Phase 3) on April 21, 2004. The approval statement describes the device as indicated for patients with osteoarthritis or avascular necrosis limited to the medial compartment of the knee, with implantation intended to use bone cement.
The device is classified as a semi-constrained, metal/polymer, mobile-bearing unicompartmental femorotibial knee prosthesis. The record does not include a supplement type or supplement reason, so no change to a prior approval is described. The statement reports the intended use but does not independently establish safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE OXFORD MENISCAL UNICOMPARTMENTAL KNEE SYSTEM (PHASE 3). THE DEVICE IS INDICATED FOR USE IN PATIENTS WITH OSTEOARTHRITIS OR AVASCULAR NECROSIS LIMITED TO THE MEDIAL COMPARTMENT OF THE KNEE AND INTENDED TO BE IMPLANTED WITH BONE CEMENT.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Apr 21, 2004
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010014
- Regulatory pathway
- Premarket approval application
- Applicant
- Biomet Manufacturing Corp
- Product code
- NRA
- Decision code
- APPR
- Decision date
- Apr 21, 2004
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, knee, femorotibial, unicompartmental, semi-constrained, metal/polymer, mobile bearing.
- Applicant
- Biomet Manufacturing Corp
- Product code
- NRA
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P010014 received
Application receipt date recorded by FDA.
P010014 · FDA decision
APPR
P010014/S118 · Related supplement
Oxford Partial Knee Anatomic Vivacit-E Meniscal Bearings
P010014/S119 · Related supplement
Cementless Oxford Partial Knee System
P010014/S120 · Related supplement
Oxford Partial Knee System
Timeline entries are records held by MedtechLedger for P010014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biomet Manufacturing Corp | PMA supplement | Sep 1, 2026 | FDA | |
Cementless Oxford Partial Knee SystemP010014/S119 | Biomet Manufacturing Corp | PMA supplement | Oct 6, 2026 | FDA |
Oxford Partial Knee SystemP010014/S120 | Biomet Manufacturing Corp | PMA supplement | Oct 26, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biomet Manufacturing Corp
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 56 E. Bell Dr.,, P.O. Box 587, Warsaw, IN, 46581
Sources and methodology
- Original FDA record: P010014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

